https://mindmedicinelaw.com/briefing/us-tightens-import-rules-for-foreign-psychedelic-suppliers-20261106-56800The Psychedelic Journalen2026-11-07T22:05:52.251442+00:00US Tightens Import Rules for Foreign Psychedelic Supplierscbp regulations, foreign importers, psychedelic research, customs brokers, controlled substances, clinical trial supply, us import compliance, supply chain risk, federal registerhttps://mindmedicinelaw.com/briefing/chemsex-prep-and-hiv-prevention-gaps-public-health-implications-20261106-57014The Psychedelic Journalen2026-11-07T22:05:40.761949+00:00Chemsex, PrEP, and HIV Prevention Gaps: Public Health Implicationschemsex, prep, hiv prevention, sexual health, structural barriers, public health policy, harm reduction, msm, integrated care, provider traininghttps://mindmedicinelaw.com/briefing/scoping-review-protocol-naturalistic-psychedelic-use-for-trauma-in-military-popu-20261106-56996The Psychedelic Journalen2026-11-07T22:05:29.261091+00:00Scoping Review Protocol: Naturalistic Psychedelic Use for Trauma in Military Populationsscoping review, psychedelics, military veterans, trauma, naturalistic settings, public health, safety, policy implications, mental health outcomeshttps://mindmedicinelaw.com/briefing/uk-scoping-review-clarifies-definitions-of-psychedelic-therapy-for-depression-20261106-57029The Psychedelic Journalen2026-11-07T22:05:18.333089+00:00UK Scoping Review Clarifies Definitions of Psychedelic Therapy for Depressionpsychedelic-assisted therapy, depression, united kingdom, clinical trials, conceptual frameworks, nhs, policy development, mental health, standardization, scoping reviewhttps://mindmedicinelaw.com/briefing/psilocybin-and-cocaine-addiction-clinical-research-and-policy-outlook-20261106-56945The Psychedelic Journalen2026-11-07T22:05:07.524762+00:00Psilocybin and Cocaine Addiction: Clinical Research and Policy Outlookpsilocybin, cocaine addiction, stimulant use disorder, clinical trials, regulatory policy, mechanism of action, psychedelic therapy, FDA, safety riskshttps://mindmedicinelaw.com/briefing/us-veterans-seek-ayahuasca-retreats-abroad-policy-and-access-gaps-20261106-56946The Psychedelic Journalen2026-11-07T22:04:55.548689+00:00US Veterans Seek Ayahuasca Retreats Abroad: Policy and Access Gapsayahuasca retreats, us veterans, psychedelic policy, mental health access, international regulation, first responders, ptsd treatment, safety risks, psychedelic therapy, policy reformhttps://mindmedicinelaw.com/briefing/exceptional-experiences-and-altered-states-implications-for-psychedelic-research-20261106-56995The Psychedelic Journalen2026-11-07T22:04:42.747126+00:00Exceptional Experiences and Altered States: Implications for Psychedelic Research Methodologyexceptional experiences, altered states of consciousness, psychedelic research, qualitative methods, phenomenology, clinical trial design, parapsychology, research ethics, FDA, non-local consciousnesshttps://mindmedicinelaw.com/briefing/ketamine-assisted-mindfulness-for-opioid-cravings-u-s-clinical-implications-20261106-57107The Psychedelic Journalen2026-11-07T22:04:31.315225+00:00Ketamine-Assisted Mindfulness for Opioid Cravings: U.S. Clinical Implicationsketamine-assisted therapy, mindfulness, opioid use disorder, body awareness, psychedelic-assisted treatment, clinical trials, regulatory policy, interoception, relapse prevention, public healthhttps://mindmedicinelaw.com/briefing/psilocybin-therapy-for-alcohol-use-disorder-evidence-review-and-policy-implicati-20261106-56994The Psychedelic Journalen2026-11-07T15:05:51.951058+00:00Psilocybin Therapy for Alcohol Use Disorder: Evidence Review and Policy Implicationspsilocybin-assisted therapy, alcohol use disorder, systematic review, randomized controlled trials, functional unblinding, clinical trial design, regulatory policy, addiction treatment, psychedelic research, evidence certaintyhttps://mindmedicinelaw.com/briefing/psychologists-seek-apa-psychedelic-science-division-policy-and-practice-implicat-20261106-56944The Psychedelic Journalen2026-11-06T22:08:03.118449+00:00Psychologists Seek APA Psychedelic Science Division: Policy and Practice Implicationsapa psychedelic division, psychologists petition, psychedelic research policy, clinical training psychedelics, institutional acceptance psychedelics, ethical standards psychedelic care, research funding psychedelics, professional legitimacy psychologyhttps://mindmedicinelaw.com/briefing/pharmacist-guidance-on-psilocybin-clinical-integration-in-the-us-20261105-57000The Psychedelic Journalen2026-11-07T22:06:02.324175+00:00Pharmacist Guidance on Psilocybin: Clinical Integration in the USpsilocybin, pharmacist education, psychedelic-assisted psychotherapy, drug interactions, clinical integration, public health, mental health policy, regulatory landscape, patient safety, interdisciplinary carehttps://mindmedicinelaw.com/briefing/psilocybin-s-astrocytic-modulation-in-nucleus-accumbens-new-mechanistic-insights-20261105-57106The Psychedelic Journalen2026-11-07T15:06:04.917850+00:00Psilocybin’s Astrocytic Modulation in Nucleus Accumbens: New Mechanistic Insightspsilocybin, astrocytes, nucleus accumbens, gene regulation, psychedelic mechanisms, clinical trial design, glial cells, FDA policy, psychiatric disordershttps://mindmedicinelaw.com/briefing/audit-finds-mdma-and-psilocybin-trials-rarely-test-trim-hypothesis-3-at-12-month-20261105-56853The Psychedelic Journalen2026-11-06T22:08:31.080598+00:00Audit Finds MDMA and Psilocybin Trials Rarely Test TRIM Hypothesis 3 at 12 Monthsmdma-assisted therapy, psilocybin therapy, randomized controlled trials, trauma-resilience integration model, trim hypothesis 3, long-term follow-up, comparator arms, clinical evidence gaps, psychedelic research, regulatory standardshttps://mindmedicinelaw.com/briefing/psilocybin-vs-ibogaine-rural-health-systems-face-strategic-choice-20261105-56832The Psychedelic Journalen2026-11-06T22:08:17.519080+00:00Psilocybin vs Ibogaine: Rural Health Systems Face Strategic Choicepsilocybin therapy, ibogaine, rural health systems, opioid use disorder, behavioral health, fda regulation, clinical evidence, psychedelic-assisted therapy, service delivery modelshttps://mindmedicinelaw.com/briefing/psilocybin-s-astrocytic-modulation-of-nucleus-accumbens-mechanism-and-implicatio-20261105-56833The Psychedelic Journalen2026-11-06T22:07:18.107581+00:00Psilocybin’s Astrocytic Modulation of Nucleus Accumbens: Mechanism and Implicationspsilocybin, nucleus accumbens, astrocytes, GABA homeostasis, NFATc4, ALDH5A1, psychedelic mechanism, translational neuroscience, mood disorders, addiction researchhttps://mindmedicinelaw.com/briefing/ketamine-s-impact-on-emotional-evidence-integration-new-insights-for-translation-20261104-56869The Psychedelic Journalen2026-11-06T22:09:05.305468+00:00Ketamine’s Impact on Emotional Evidence Integration: New Insights for Translational Psychiatryketamine, emotional evidence integration, affective disorders, clinical trial design, nmda receptor antagonist, environmental volatility, translational psychiatry, neurocognitive mechanisms, psychedelic researchhttps://mindmedicinelaw.com/briefing/oral-ketamine-for-resistant-depression-evidence-protocols-and-policy-gaps-20261104-56877The Psychedelic Journalen2026-11-06T22:08:53.538518+00:00Oral Ketamine for Resistant Depression: Evidence, Protocols, and Policy Gapsoral ketamine, treatment-resistant depression, suicidality, dosing protocols, randomized controlled trials, psychiatric policy, adverse effects, clinical guidelines, regulatory approvalhttps://mindmedicinelaw.com/briefing/phase-2-trial-itbs-extends-ketamine-response-in-trd-patients-20261104-56879The Psychedelic Journalen2026-11-06T22:08:42.690902+00:00Phase 2 Trial: iTBS Extends Ketamine Response in TRD Patientstreatment-resistant depression, ketamine, intermittent theta burst stimulation, iTBS, clinical trial, phase 2, brain connectivity, neuromodulation, combination therapy, fMRIhttps://mindmedicinelaw.com/briefing/polydrug-use-and-ptsd-insights-from-mass-trauma-survivors-in-israel-20261103-56854The Psychedelic Journalen2026-11-07T15:06:46.253539+00:00Polydrug Use and PTSD: Insights from Mass Trauma Survivors in Israelpolydrug use, ptsd, mass trauma, psychedelics, recreational motives, self-medication, nova festival, public health, substance use patternshttps://mindmedicinelaw.com/briefing/bdnf-pathway-as-a-target-for-treatment-resistant-depression-mechanistic-insights-20261103-56880The Psychedelic Journalen2026-11-07T15:06:33.587941+00:00BDNF Pathway as a Target for Treatment-Resistant Depression: Mechanistic Insights and Clinical Implicationsbdnf, treatment-resistant depression, neuroplasticity, psychedelic research, precision psychiatry, epigenetics, clinical trial design, biomarkers, genetic polymorphismhttps://mindmedicinelaw.com/briefing/ketamine-s-anti-dyskinetic-effects-in-female-parkinson-s-models-preclinical-evid-20261103-56883The Psychedelic Journalen2026-11-07T15:06:18.493522+00:00Ketamine’s Anti-Dyskinetic Effects in Female Parkinson’s Models: Preclinical Evidence and Implicationsketamine, parkinson's disease, l-dopa-induced dyskinesia, sex differences, preclinical models, female rats, clinical trial design, regulatory policy, neuropharmacologyhttps://mindmedicinelaw.com/briefing/discovery-of-naadp-lysosomal-pathway-in-5-ht2a-psychedelic-signaling-20261103-56881The Psychedelic Journalen2026-11-06T22:07:41.174356+00:00Discovery of NAADP-Lysosomal Pathway in 5-HT2A Psychedelic Signaling5-ht2a receptor, naadp, lysosomal calcium, psychedelic mechanism, neuroplasticity, hallucinogenic effects, drug development, clinical translation, intracellular signalinghttps://mindmedicinelaw.com/briefing/psilocybin-therapy-for-cancer-distress-systematic-review-insights-20261103-56838The Psychedelic Journalen2026-11-06T22:07:29.939087+00:00Psilocybin Therapy for Cancer Distress: Systematic Review Insightspsilocybin-assisted therapy, cancer-related distress, systematic review, existential distress, depression and anxiety, palliative care, clinical trial design, adverse events, regulatory policy, psychedelic researchhttps://mindmedicinelaw.com/briefing/systematic-review-no-effective-drugs-for-prolonged-grief-disorder-20261102-56842The Psychedelic Journalen2026-11-07T15:07:39.751085+00:00Systematic Review: No Effective Drugs for Prolonged Grief Disorderprolonged grief disorder, systematic review, pharmacological treatment, psychedelic-assisted therapy, clinical trials, mental health policy, bereavement, antidepressants, regulatory implicationshttps://mindmedicinelaw.com/briefing/ohio-state-launches-psilocybin-trial-for-depression-in-lung-cancer-patients-20261102-56943The Psychedelic Journalen2026-11-07T15:07:25.891657+00:00Ohio State Launches Psilocybin Trial for Depression in Lung Cancer Patientspsilocybin therapy, lung cancer depression, ohio state university trial, oncology psychedelics, clinical trial phase, palliative care innovation, fda regulation, mental health in cancer, psychedelic-assisted therapyhttps://mindmedicinelaw.com/briefing/music-therapy-and-psychedelics-in-psychiatric-care-review-and-implications-20261102-56844The Psychedelic Journalen2026-11-07T15:07:13.171947+00:00Music Therapy and Psychedelics in Psychiatric Care: Review and Implicationsmusic therapy, psychedelic treatment, psychiatric disorders, clinical trial design, depression, anxiety, ptsd, neural mechanisms, treatment protocolshttps://mindmedicinelaw.com/briefing/enantioselective-ketamine-analysis-in-pink-cocaine-forensic-and-policy-implicati-20261102-56888The Psychedelic Journalen2026-11-07T15:07:00.180605+00:00Enantioselective Ketamine Analysis in 'Pink Cocaine': Forensic and Policy Implicationsketamine enantiomers, pink cocaine, forensic drug analysis, capillary electrophoresis, high-performance liquid chromatography, drug diversion, chiral surveillance, public health monitoring, law enforcement, illicit drug markethttps://mindmedicinelaw.com/briefing/ketamine-s-cell-type-specific-modulation-of-serotonergic-neurons-mechanistic-ins-20261101-57054The Psychedelic Journalen2026-11-07T22:04:19.139118+00:00Ketamine’s Cell-Type-Specific Modulation of Serotonergic Neurons: Mechanistic Insights for Antidepressant Researchketamine, serotonergic neurons, dorsal raphe nucleus, trkB pathway, rapid antidepressants, cell-type specificity, biomarkers, clinical trial design, psychedelic research, mechanistic insightshttps://mindmedicinelaw.com/briefing/ketamine-bladder-toxicity-clinical-and-policy-implications-global-2026-20261101-56899The Psychedelic Journalen2026-11-07T15:07:54.278016+00:00Ketamine Bladder Toxicity: Clinical and Policy Implications (Global, 2026)ketamine bladder toxicity, urinary tract complications, psychedelic therapy safety, bladder dysfunction, clinical protocols, regulatory policy, risk mitigation, psychiatric indications, adverse events monitoringhttps://mindmedicinelaw.com/briefing/fireside-project-s-25-000-psychedelic-support-dataset-us-evidence-for-policy-and-20261030-56851The Psychedelic Journalen2026-11-06T22:07:51.965600+00:00Fireside Project's 25,000+ Psychedelic Support Dataset: US Evidence for Policy and Practicefireside project, psychedelic support, harm reduction, peer support dataset, psilocybin use, cannabis distress, public health policy, nonclinical psychedelic use, volunteer training, epidemiology